Young-onset dementia charity expands activities in Woking
What are dementia and Alzheimer's?How does young-onset dementia affect people?'Groundbreaking' dementia trial starts in Surrey
Mr Goodman told BBC Radio Surrey: "We're providing activity and social interaction for the person living with dementia, but we're also providing respite for their carers because, more often than not, carers are in full-time work when their partner's diagnosed."There's not as much opportunity for them for help," he said. "We've worked with people as young as in their 30s, so [dementia] is something that really doesn't discriminate."
The charity runs gardening workshops, a choir, cookery classes and racket sport events, changing activities every six weeks.Ian, one of the service users, said the group had "become a community"."The variety of people and personalities is what makes it special," he said."The choir is the one where there's most people, about 40, maybe 50."There's no stigma, everyone's accepted by default," Ian said. "At the end of the day we're just human beings getting on with life as best we can."People under 65 who have a diagnosis of dementia can self-refer through the charity's website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 hours ago
- Daily Mail
Father-of-two, 39, thought stomach pain was from 'dodgy sausage' at BBQ... but it was colon cancer - doctors gave him 'months to live'
The first sign something was wrong for Matt Eamer came just days after a family barbeque, celebrating his son's second birthday. The then 39-year-old father-of-two from Redhill, Surrey, dismissed the sudden 'spiky' stomach pain as food poisoning. 'I was speaking to work colleagues over the first week or two and thought I'd cooked a dodgy sausage,' he said. But his pain escalated quickly. After a rushed trip to A&E he was sent home with anti-nausea medication Buscopan, yet still felt dreadful. His wife Sarah, 41, a doula, took him to East Surrey Hospital where scans revealed a 'big blockage' in his large intestine. Surgeons removed two-thirds of his bowel in an emergency op. 'A few days later they confirmed it was cancer,' Matt said. The diagnosis was stage four bowel cancer. The disease had already spread to his liver and the lining of his abdomen, and further tests revealed a rare BRAF mutation which drives tumours to grow at speed. 'I can still remember the person's voice when she phoned and said, "the plan for your diagnosis has changed… we're talking months not years from a survival point of view",' Matt recalled of the events in September 2020. On his 40th birthday he was told standard chemotherapy had failed and surgeons found the cancer had advanced further. 'It was a very dramatic, movie-like point,' he said. 'It was a pivotal change. They said, "we've gone in, it's gone further, we're going to try these new drugs." My wife Sarah collapsed to the floor.' Matt began fortnightly Cetuximab infusions combined with four daily Encorafenib pills, new immunotherapy drugs approved just months earlier. Designed to buy only 'three to six months', they had a remarkable effect. Within six months, scans showed no trace of cancer. Five years on, he is still clear and continues treatment. 'Hitting five years with stage four is a rarity,' he said. 'You're not on your death bed but you're forced to think about how you spend your time.' In December 2024, he underwent a 14-hour surgery to remove cancerous tissue in his ribcage, followed by heated HIPEC chemotherapy. The disease had already spread to his liver and the lining of his abdomen, and further tests revealed a rare BRAF mutation which drives tumours to grow at speed. Again, scans showed 'things clear.' Matt, who runs his own design agency, continues working and raising his two children. 'The reality is younger people are able to deal with treatments better and live longer, better lives even if it is stage four,' he said. He adds: 'The reality is the 'bucket and spade things', the little moments. I spend more time looking at my kids' faces, taking them to a show or swimming in the sea — they are heightened. 'It means your ability to be present and focus upon what matters is heightened.' To mark five years since his diagnosis, Matt will join Sir Chris Hoy's charity cycle in Glasgow on September 7, raising funds for Bowel Cancer UK. 'It's marking a milestone in a meaningful, positive way,' he said. Bowel cancer, also known as colorectal cancer, is one of the most common cancers in both Britain and the United States. In the UK around 43,000 people are diagnosed every year, while in the US the figure is more than 150,000. It is the third most common cancer worldwide and the second leading cause of cancer deaths. In older age groups incidence is declining thanks to better screening and awareness, yet in younger people rates are rising sharply, a trend baffling doctors. In England cases among those aged 25 to 49 have surged by around 3.6 per cent per year, one of the steepest increases in Europe, while in America rates in under-50s have been rising by about 2.4 per cent annually over the past decade. Outcomes depend heavily on how early the disease is caught. In the UK one-year survival is around 97 per cent if picked up through screening, but just 49 per cent if discovered in an emergency admission, as was the case for Matt. In the US five-year survival is 92 per cent at stage one but only 13 per cent at stage four. Most people with a diagnosis as advanced as Matt's do not reach the five-year mark, making his story unusual. Risk factors include family history, inflammatory bowel disease, obesity, alcohol, smoking, and diets low in fibre and high in red or processed meats. Researchers are also examining the role of ultra-processed foods, though evidence remains inconclusive, and some studies point to gut bacteria toxins such as colibactin, found in food poisoning, as a possible trigger for early-onset cases. Screening programmes remain vital. In the US guidelines now recommend testing from age 45, while in the UK stool tests are currently offered from 56, with pilot schemes lowering the age to 50. Symptoms to watch for include persistent changes in bowel habits, blood in stools, unexplained weight loss, abdominal pain or bloating, and lumps in the abdomen. Doctors stress that catching the disease early saves lives. Patients diagnosed at stage one are several times more likely to survive long term than those at stage four. But as Matt's case shows, advances in treatment—from new targeted drugs to more effective surgery—are beginning to change what is possible, even in the most serious cases. For him, the experience has redefined life. 'The reality isn't bucket-list dolphins—it's the bucket and spade things,' he said.
The Independent
3 hours ago
- The Independent
Type 2 diabetes patients set for major shake-up in care
People with type 2 diabetes in England are to get the biggest shake up of care in a decade which could see them offered treatments, including jabs that aid weight-loss, sooner. The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
BBC News
3 hours ago
- BBC News
More weight-loss drugs offered in type 2 diabetes care shake-up
Treatment for millions of people with type 2 diabetes should be more personalised, with greater access to newer medicines, including weight-loss drugs, the healthcare assessment body for England, Wales and Northern Ireland has calls the move "the biggest shake-up" in type 2 diabetes care in a more people the new drugs will prevent complications such as heart disease, strokes and kidney damage, reduce costs to the NHS and potentially save lives, the National Institute for Health and Care Excellence (NICE) says. Around 4.6 million people in the UK are diagnosed with diabetes - of these 90% have type 2, with another 1.3 million likely to be undiagnosed. Having type 2 diabetes means there is too much glucose or sugar in the blood. This makes strokes, heart attacks, heart failure and other health conditions much more of a risk. It is now so common that 10% of the NHS budget goes towards treating which produces guidance for the NHS on how to give patients the best care, recommends a move away from a "one size fits all" approach and towards more personalised is calling for newer diabetes medicines called SGLT-2 inhibitors, which protect the heart and kidneys as well as lowering blood sugar levels, to become the first-choice treatment for all diabetes patients. Around 2.3 million people will be eligible for these 22,000 lives could be saved if 90% of all diabetes patients were prescribed them, NICE says, but access is not equal across the UK. There is evidence that women, older people and black people are less likely to be prescribed them."There is some urgency to find ways to increase the uptake of SGLT-2 inhibitors because if we were to achieve perfect uptake, the nation would be significantly healthier," said Dr Waqaar Shah, chair of the guideline one in five people with type 2 diabetes and cardiovascular disease are currently prescribed the the tablets to more people would particularly benefit those living in poorer areas and ethnic minorities, NICE says. Under the guidance, which is still at a draft stage and needs to go through a consultation, around 750,000 more people with type 2 diabetes will be offered GLP-1 agonists such as semaglutide and liraglutide, which have become very popular as the drugs contained in weight-loss with cardiovascular disease and some who develop type 2 before they are 40 are the groups recommended to be offered drugs can be used both to lower blood sugar levels and to support some people with weight Jonathan Benger, deputy chief executive and chief medical officer at NICE, said the updated guidance was "a significant evolution" in type 2 diabetes treatment which could help prevent heart attacks, strokes and other serious complications before they happen."This guidance means more people will be offered medicines, where it is right to do so, to reduce their future risk of ill health," he guidelines are part of a long-term plan by the NHS in England to reduce health inequalities and focus on preventing ill health in the first charity Diabetes UK said the announcement propelled type 2 diabetes treatments "into the 21st century"."These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes," said Douglas Twenefour, head of clinical at the charity.
